SELLAS Life Sciences Grou... (SLS)

NasdaqCM: SLS · Real-Time Price · USD

13.49

+0.39 (2.98%)

At close: Aug 19, 2026, 3:35 PM

2.98% (1D)

No data available

Bid	n/a
Market Cap	2.72B
Revenue (ttm)	n/a
Net Income (ttm)	-32.46M
Beta	2.49
EPS (ttm)	-0.22
PE Ratio (ttm)	n/a
Forward PE	-134.94
P/B (ttm)	22.79
P/S (ttm)	n/a
Earnings Date	Nov 11, 2026

Ask	n/a
Volume	2,373,838
Avg. Volume (20D)	9,074,500
Open	13.46
Previous Close	13.10
Day's Range	13.00 - 13.63
52-Week Range	1.39 - 15.88
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About SLS

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration w...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 12, 2008

Employees 13

Stock Exchange NasdaqCM

Ticker Symbol SLS

Website https://sellaslifesciences.com

Full Company Profile

Financial Performance

In 2025, SELLAS Life Sciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -26.86M, a decrease of -13.01%.

Financial Statements

Earnings Surprise

SELLAS Life Sciences has released their quarterly earnings on Aug 11, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.05 misses estimates by -0.01, with 28.57% YoY growth.

Next Earnings Release

SELLAS Life Sciences Group Inc. is scheduled to release its earnings on Nov 11, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

1 day ago · Stocktwits

SLS Stock Extends Rally To 4 Days: Jefferies Discloses New Stake, CEO Signals AML Database-Lock Preparations

A separate pediatric study delivered “striking” WT1 vaccine results, supporting GPS’s scientific rationale, the company's CEO said.

1 day ago · Stocktwits

Sellas CEO Angelos Stergiou Highlights Pediatric Leukemia Study That ‘Directly Supports’ Scientific Basis Of Regal Trial

Stergiou highlighted a Phase 2 study published in the Blood Advances journal that evaluated a maintenance therapy in 17 children with hard-to-treat acute leukemia following stem-cell transplants.